Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022
Engineered for Severe Obesity and Complex Metabolic Disorders Retatrutides triple-agonist model is intended to help individuals with strong metabolic resistance, such as those who: plateau on semaglutide struggle with long-term weight maintenance experience rapid metabolic slowdown during dieting have severe insulin resistance or fatty liver issues Potential Beyond Weight Management Ongoing studies are exploring retatrutides ability to improve: insulin sensitivity liver-fat clearance cardiovascular risk markers inflammatory markers stabilization of long-term metabolic function These features suggest retatrutide may evolve into a broader therapeutic option than current GLP-1 drugs
Discontinuation rates were higher than in Phase 2 trials - 18.2% at the 12mg dose versus 4% with placebo
These findings suggest that this type of thyroid dysfunction results from thyroid gland destruction induced by anti-PD-1 antibodies
Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction
Motivation & Faster Music (00:50:49) Tool: Cognitive Work & Binaural Beats (00:54:11) Silence or Music for Studying?, White Noise, Binaural Beats (00:58:47) Tool: Retain Information & Internal Dialogue (01:00:53) Tool: Focus, Work Breaks & Music (01:04:11) Physical Exercise, Performance & Music (01:07:37) Sponsor: InsideTracker (01:08:43) Music & Shifting Mood (01:14:41) Happy vs
US$ 22.36
US$ 25.86
US$ 24.27
US$ 25.11
